varied timing of io therapy in patients with stage iii nsclc
Published 4 years ago • 55 plays • Length 7:34Download video MP4
Download video MP3
Similar videos
-
7:26
personal use of i-o therapy in advanced-stage nsclc
-
7:44
immunotherapy in stage iii nsclc
-
5:56
multidisciplinary management of patients with stage iii nsclc
-
11:00
i-o options for stage iii nsclc & international pd-l1 restrictions
-
6:06
stage iii nsclc: when to start durvalumab
-
7:44
immunotherapy in stage iii nsclc
-
4:34
pembrolizumab treatment in stage iii nsclc and alternatives
-
4:43
a retrospective study of outcomes with ven-based treatment in cbtki-treated, chemotherapy-naïve cll
-
5:58
continuing/re-challenging with i-o therapy in nsclc
-
5:43
duration of upfront immunotherapy for nsclc
-
9:57
practical considerations for immunotherapy in stage 3 nsclc
-
1:08:00
has immunotherapy brought us to an inflection point in the management of stage i-iii nsclc?
-
4:37
immunotherapy in early stage nsclc
-
25:26
locally advanced nsclc: combination therapy with targeted and immunotherapy agents
-
4:07
chemotherapy with i-o therapy in egfr- or alk-mutated nsclc
-
6:20
immunotherapy in stage iii nsclc: practice-changing results of pacific trial (bmic-006)
-
4:19
immune checkpoint therapy overview for stage iii nsclc
-
1:13
immunotherapy in stage iii nsclc metastatic disease
-
7:35
i-o therapy versus surgery or chemotherapy in nsclc